This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rodríguez-Cerrato, V.
Right arrow Articles by Soriano, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodríguez-Cerrato, V.
Right arrow Articles by Soriano, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2007, p. 3371-3373, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00137-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

Pneumococcal LytA Autolysin, a Potent Therapeutic Agent in Experimental Peritonitis-Sepsis Caused by Highly ß-Lactam-Resistant Streptococcus pneumoniae{triangledown}

Violeta Rodríguez-Cerrato,1 Pedro García,2 Lorena Huelves,1 Ernesto García,2 Gema del Prado,1 Matilde Gracia,1 Carmen Ponte,1 Rubens López,2 and Francisco Soriano1*

Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz, Madrid, Spain,1 Department of Molecular Microbiology, Centro de Investigaciones Biológicas (CSIC), Ramiro de Maeztu 9, 28040 Madrid, Spain2

Received 30 January 2007/ Returned for modification 30 April 2007/ Accepted 9 June 2007

The in vitro and in vivo antipneumococcal activities of the main pneumococcal autolysin (LytA) and Cpl-1, a lysozyme encoded by phage Cp-1, were studied. Intraperitoneal therapy with LytA or high-dose Cpl-1 remarkably reduced peritoneal bacterial counts (>5 log10 CFU/ml) compared with those for the controls. After intravenous injection, LytA was the most effective treatment.

* Corresponding author. Mailing address: Department of Medical Microbiology and Antimicrobial Chemotherapy, Fundación Jiménez Díaz, Avenida de Reyes Católicos 2, 28040 Madrid, Spain. Phone: 34-91-544-73-87. Fax: 34-91-549-47-64. E-mail: fsoriano{at}fjd.es

{triangledown} Published ahead of print on 18 June 2007.

Antimicrobial Agents and Chemotherapy, September 2007, p. 3371-3373, Vol. 51, No. 9
0066-4804/07/$08.00+0     doi:10.1128/AAC.00137-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»